TCTMD

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

MIAMI, FL – A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an ...
FiercePharma

Phase II Study Showed Switching ACS-PCI Patients to Effient®/aspirin from Plavix®/aspirin Regimen Reduced Maximum Platelet Aggre

The SWAP study was not designed to evaluate efficacy or safety endpoints. Study Methodology SWAP was a Phase II, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating ...
FierceBiotech

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel

The study enrolled 13,608 patients at 707 trial sites in 30 countries. The primary endpoint of the study was to compare the effects of prasugrel to clopidogrel on the composite incidence of ...
TCTMD

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Patients with chronic or acute coronary syndromes undergoing PCI have comparable safety and efficacy outcomes at 1 year no matter whether they were initially discharged on aspirin plus prasugrel or ...
Drug Store News

Study: Effient achieves greater platelet inhibition in Type 2 diabetes with CAD patients

ORLANDO, Fla. Patients with Type 2 diabetes and coronary heart disease showed greater reduction in platelet activity in the blood when taking a new drug from Eli Lilly & Co. and Daiichi-Sankyo than ...
FierceBiotech

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel

Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents CHICAGO, March 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- ...